Company: Merck (MSD)
Tags: pipeline, territory
Keytruda has more indications than I can keep straight. I'm not exaggerating — there are so many approved combinations and tumor types that even experienced oncology reps get confused in front of physicians. The breadth that makes it commercially powerful also makes it operationally exhausting. Medical questions come in from left field. Clinical nuance is real. BMS reps have it easier in some ways because they have fewer things to know. I'm not complaining about working on the most successful cancer drug in history. But if you're joining the Merck oncology team expecting a clean story, prepare
26 upvotes · 0 comments